As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent ...
Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
iPSCore platform delivered over 500 characterized iPSC lines during first year of collaboration SAN DIEGO, March 11, 2026--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. ("iXCells"), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results